Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 3Plasma cell 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Myelodysplastic Syndromes 1Multiple Myeloma 1Lymphoma 1Leukemia, Myeloid, Acute 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hematologic Neoplasms 1

Interventions

Rituximab 376Cyclophosphamide 179Bendamustine Hydrochloride 109obinutuzumab 100Vincristine 94fludarabine 92ibrutinib 89Prednisone 89Doxorubicin 89venetoclax 86Lenalidomide 82Gemcitabine 65acalabrutinib 48Brentuximab Vedotin 44pembrolizumab 43zanubrutinib 41Dexamethasone 41idelalisib 37ofatumumab 32Oxaliplatin 30Chlorambucil 29polatuzumab vedotin 25blinatumomab 25tocilizumab 24Azacitidine 24tositumomab I-131 22Prednisolone 22tisagenlecleucel 21glofitamab 21Nivolumab 21

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × domatinostat × Lymphoid × Clear all
NCT01344707 2015-04-01

Oral Histone Deacetylase Inhibitor 4SC-202 in Patients With Advanced Hematologic Malignancies (TOPAS)

4SC AG

Phase 1 Completed
36 enrolled
LymphoidMyeloidOther hematologic neoplasmPlasma cell

Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡